Clinical trial
Fosamprenavir Versus Other Protease Inhibitors
NCT00094523 · ViiV Healthcare, Industry · Completed
Key facts
| NCT number | NCT00094523 |
|---|---|
| Title | Fosamprenavir Versus Other Protease Inhibitors |
| Official title | A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks |
| Lead sponsor | ViiV Healthcare, Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infection, Human Immunodeficiency Virus I |
| Intervention type | Drug |
| Interventions | Fosamprenavir |
| Enrollment | 314 |
| Start date | Dec 14, 2004 |
| Primary completion | Jun 29, 2007 |
| Completion | Jun 29, 2007 |
| First posted | Oct 21, 2004 |
| Last update posted | Apr 18, 2018 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: